Patents by Inventor Jorge E. Osorio

Jorge E. Osorio has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240316185
    Abstract: Disclosed herein are mosaic coronavirus (MoCoV) spike(S) proteins or antigenic fragments thereof. Also disclosed herein are nucleic acid constructs comprising one or more nucleic acid sequences encoding a MoCoV S protein or antigenic fragment thereof. Also disclosed herein are coronavirus vaccine vectors comprising one or more polynucleotides encoding a MoCoV S protein or antigenic fragment thereof. Also disclosed herein are coronavirus vaccines comprising one or more MoCoV S proteins or antigenic fragments thereof and one or more carriers. Also disclosed herein are pharmaceutical compositions, host cells, and kits comprising one or more of the MoCoV S proteins or antigenic fragments thereof, nucleic acid constructs, coronavirus vaccine vectors, and/or coronavirus vaccines.
    Type: Application
    Filed: June 4, 2024
    Publication date: September 26, 2024
    Inventor: Jorge E. OSORIO
  • Patent number: 12005114
    Abstract: Disclosed herein are mosaic coronavirus (MoCoV) spike (S) proteins or antigenic fragments thereof. Also disclosed herein are nucleic acid constructs comprising one or more nucleic acid sequences encoding a MoCoV S protein or antigenic fragment thereof. Also disclosed herein are coronavirus vaccine vectors comprising one or more polynucleotides encoding a MoCoV S protein or antigenic fragment thereof. Also disclosed herein are coronavirus vaccines comprising one or more MoCoV S proteins or antigenic fragments thereof and one or more carriers. Also disclosed herein are pharmaceutical compositions, host cells, and kits comprising one or more of the MoCoV S proteins or antigenic fragments thereof, nucleic acid constructs, coronavirus vaccine vectors, and/or coronavirus vaccines.
    Type: Grant
    Filed: January 19, 2023
    Date of Patent: June 11, 2024
    Assignee: VAXTHERA SAS
    Inventor: Jorge E. Osorio
  • Publication number: 20230256087
    Abstract: Disclosed herein are mosaic coronavirus (MoCoV) spike (S) proteins or antigenic fragments thereof. Also disclosed herein are nucleic acid constructs comprising one or more nucleic acid sequences encoding a MoCoV S protein or antigenic fragment thereof. Also disclosed herein are coronavirus vaccine vectors comprising one or more polynucleotides encoding a MoCoV S protein or antigenic fragment thereof. Also disclosed herein are coronavirus vaccines comprising one or more MoCoV S proteins or antigenic fragments thereof and one or more carriers. Also disclosed herein are pharmaceutical compositions, host cells, and kits comprising one or more of the MoCoV S proteins or antigenic fragments thereof, nucleic acid constructs, coronavirus vaccine vectors, and/or coronavirus vaccines.
    Type: Application
    Filed: January 19, 2023
    Publication date: August 17, 2023
    Inventor: Jorge E. OSORIO
  • Publication number: 20220118074
    Abstract: A flavivirus virus-like particle and methods of making and using that particle, and antibodies raised to a plurality of those particles, arc provided.
    Type: Application
    Filed: September 16, 2021
    Publication date: April 21, 2022
    Inventors: Brock Adam Kingstad-Bakke, Jorge E. Osorio
  • Patent number: 11197923
    Abstract: Embodiments herein relate to compositions of and methods for live viruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated viruses and compositions to reduce inactivation and/or degradation of the live, attenuated virus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated virus composition may include at least one carbohydrate, at least one protein and at least one high molecular weight surfactants for reducing inactivation and/or degradation of the live, attenuated virus.
    Type: Grant
    Filed: November 22, 2019
    Date of Patent: December 14, 2021
    Assignee: Takeda Vaccines, Inc.
    Inventors: Dan Stinchcomb, Jorge E. Osorio, O'Neil Wiggan
  • Patent number: 10806782
    Abstract: The present disclosure relates to hand, foot, and mouth disease vaccines and immunogenic compositions having one or more antigens from at least one virus that causes hand, foot, and mouth disease in humans, and methods of manufacture, formulation, and testing, and uses thereof.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: October 20, 2020
    Assignee: Takeda Vaccines, Inc.
    Inventors: Subash Chandra Das, Joseph David Santangelo, Dan Thomas Stinchcomb, Jorge E. Osorio
  • Patent number: 10729758
    Abstract: The invention provides for mosaic influenza virus HA and NA sequences and uses thereof.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: August 4, 2020
    Assignee: Wisconsin Alumni Research Foundation (WARF)
    Inventors: Jorge E. Osorio, Tony Goldberg, Attapon Kamlangdee, Brock Adam Kingstad-Bakke, Tavis Anderson
  • Publication number: 20200108136
    Abstract: Embodiments herein relate to compositions of and methods for live viruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated viruses and compositions to reduce inactivation and/or degradation of the live, attenuated virus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated virus composition may include at least one carbohydrate, at least one protein and at least one high molecular weight surfactants for reducing inactivation and/or degradation of the live, attenuated virus.
    Type: Application
    Filed: November 22, 2019
    Publication date: April 9, 2020
    Inventors: Dan STINCHCOMB, Jorge E. OSORIO, O'Neil WIGGAN
  • Patent number: 10525120
    Abstract: Embodiments herein relate to compositions of and methods for live viruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated viruses and compositions to reduce inactivation and/or degradation of the live, attenuated virus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated virus composition may include at least one carbohydrate, at least one protein and at least one high molecular weight surfactants for reducing inactivation and/or degradation of the live, attenuated virus.
    Type: Grant
    Filed: July 22, 2016
    Date of Patent: January 7, 2020
    Assignee: TAKEDA VACCINES, INC.
    Inventors: Dan Stinchcomb, Jorge E. Osorio, O'Neil Wiggan
  • Patent number: 10233429
    Abstract: The present disclosure relates to hand, foot, and mouth disease vaccines and immunogenic compositions having one or more antigens from at least one virus that causes hand, foot, and mouth disease in humans, and methods of manufacture, formulation, and testing, and uses thereof.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: March 19, 2019
    Assignee: Takeda Vaccines, Inc.
    Inventors: Subash Chandra Das, Joseph David Santangelo, Dan Thomas Stinchcomb, Jorge E. Osorio
  • Publication number: 20180228887
    Abstract: Embodiments of the present invention report compositions and methods for vaccinating a subject using trivalent dengue virus vaccine compositions. In some embodiments, more than one vaccine composition may be administered to a subject in different anatomical locations in order to induce a rapid response to at least three of four dengue virus serotypes. In certain embodiments, administration of a trivalent dengue virus vaccine composition can be combined with administration of a monovalent dengue virus vaccine composition.
    Type: Application
    Filed: December 15, 2017
    Publication date: August 16, 2018
    Inventors: Dan T. Stinchcomb, Joseph N. Brewoo, Jorge E. Osorio, Charalambos D. Partidos
  • Publication number: 20180187165
    Abstract: The present disclosure relates to hand, foot, and mouth disease vaccines and immunogenic compositions having one or more antigens from at least one virus that causes hand, foot, and mouth disease in humans, and methods of manufacture, formulation, and testing, and uses thereof.
    Type: Application
    Filed: October 27, 2017
    Publication date: July 5, 2018
    Applicant: Takeda Vaccines, Inc.
    Inventors: Subash Chandra DAS, Joseph David SANTANGELO, Dan Thomas STINCHCOMB, Jorge E. OSORIO
  • Patent number: 10010600
    Abstract: Embodiments of the present invention report compositions and methods for vaccinating a subject against dengue viruses. In some embodiments, vaccine compositions may be administered by intradermal introduction. In certain embodiments, intradermal introduction in a subject of a vaccine against dengue virus may include one or more intradermal boosts after initial vaccination. Other embodiments include intradermal injection of a vaccine composition against dengue virus wherein the composition provides protection against two or more of DEN-1, DEN-2, DEN-3 and DEN-4.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: July 3, 2018
    Assignee: TAKEDA VACCINES, INC.
    Inventors: Dan T. Stinchcomb, Jorge E. Osorio, Charalambos D. Partidos, Joseph N. Brewoo
  • Publication number: 20180125965
    Abstract: The present disclosure relates to hand, foot, and mouth disease vaccines and immunogenic compositions having one or more antigens from at least one virus that causes hand, foot, and mouth disease in humans, and methods of manufacture, formulation, and testing, and uses thereof. Thus, there is a need to develop vaccines and immunogenic compositions for treating and/or preventing hand, food, and mouth disease, particularly in children. In order to meet this need, the present disclosure provides vaccines and immunogenic compositions for treating and/or preventing hand, foot, and mouth disease that include antigens from at least one virus that causes hand, foot, and mouth disease in humans, such as EV71, CA6, and CA16.
    Type: Application
    Filed: November 6, 2015
    Publication date: May 10, 2018
    Applicant: Takeda Vaccines, Inc.
    Inventors: Subash Chandra DAS, Joseph David SANTANGELO, Dan Thomas STINCHCOMB, Jorge E. OSORIO
  • Publication number: 20180028643
    Abstract: A flavivirus virus-like particle and methods of making and using that particle, and antibodies raised to a plurality of those particles, are provided.
    Type: Application
    Filed: June 21, 2017
    Publication date: February 1, 2018
    Inventors: Brock Adam Kingstad-Bakke, Jorge E. Osorio
  • Patent number: 9878031
    Abstract: Embodiments of the present invention report compositions and methods for vaccinating a subject using trivalent dengue virus vaccine compositions. In some embodiments, more than one vaccine composition may be administered to a subject in different anatomical locations in order to induce a rapid response to at least three of four dengue virus serotypes. In certain embodiments, administration of a trivalent dengue virus vaccine composition can be combined with administration of a monovalent dengue virus vaccine composition.
    Type: Grant
    Filed: December 7, 2013
    Date of Patent: January 30, 2018
    Assignee: Takeda Vaccines, Inc.
    Inventors: Dan T. Stinchcomb, Joseph N. Brewoo, Jorge E. Osorio, Charalambos D. Partidos
  • Publication number: 20180008691
    Abstract: Embodiments of the present invention report compositions and methods for vaccinating a subject against all dengue virus serotypes. In some embodiments, multiple vaccine compositions may be administered to a subject in different anatomical locations in order to induce a rapid response to all dengue virus serotypes. In certain embodiments, administration of two or more vaccine compositions to a subject against all dengue virus serotypes may include two or more routes of administration.
    Type: Application
    Filed: June 16, 2017
    Publication date: January 11, 2018
    Inventors: Dan T. Stinchcomb, Jorge E. Osorio, Charalambos D. Partidos, Joseph N. Brewoo
  • Patent number: 9834757
    Abstract: The present disclosure relates to hand, foot, and mouth disease vaccines and immunogenic compositions having one or more antigens from at least one virus that causes hand, foot, and mouth disease in humans, and methods of manufacture, formulation, and testing, and uses thereof.
    Type: Grant
    Filed: November 6, 2015
    Date of Patent: December 5, 2017
    Assignee: Takeda Vaccines, Inc.
    Inventors: Subash Chandra Das, Joseph David Santangelo, Dan Thomas Stinchcomb, Jorge E. Osorio
  • Patent number: 9713638
    Abstract: Embodiments of the present invention report compositions and methods for vaccinating a subject against all dengue virus serotypes. In some embodiments, multiple vaccine compositions may be administered to a subject in different anatomical locations in order to induce a rapid response to all dengue virus serotypes. In certain embodiments, administration of two or more vaccine compositions to a subject against all dengue virus serotypes may include two or more routes of administration.
    Type: Grant
    Filed: June 10, 2013
    Date of Patent: July 25, 2017
    Assignee: Takeda Vaccines, Inc.
    Inventors: Dan T. Stinchcomb, Jorge E. Osorio, Charalambos D. Partidos, Joseph N. Brewoo
  • Publication number: 20170100474
    Abstract: Embodiments herein relate to compositions of and methods for live viruses. In certain embodiments, a live, attenuated virus composition includes, but is not limited to, one or more live, attenuated viruses and compositions to reduce inactivation and/or degradation of the live, attenuated virus. In other embodiments, the live, attenuated virus composition may be a vaccine composition. In yet other compositions, a live, attenuated virus composition may include at least one carbohydrate, at least one protein and at least one high molecular weight surfactants for reducing inactivation and/or degradation of the live, attenuated virus.
    Type: Application
    Filed: July 22, 2016
    Publication date: April 13, 2017
    Inventors: Dan Stinchomb, Jorge E. Osorio, O'Neil Wiggan